Shree Ganesh Biotech (India) Limited has submitted a regulatory disclosure to BSE Limited, The Calcutta Stock Exchange Ltd, and Metropolitan Stock Exchange of India Limited regarding the utilization of funds from past capital raising activities.
The disclosure is made pursuant to SEBI Circular CIR/CFD/CMD1/162/2019 dated 24th December, 2019, which requires statements on deviation or variation for proceeds of public issue, rights issue, preferential issue, or qualified institutional placement (QIP).
The company specifically states that it does not have any funds remaining unutilized as on 30th June 2026, or as on the date of the disclosure (04.08.2026), out of the proceeds of any public issue, rights issue, preferential issue, or qualified institutional placement (QIP) undertaken by the company at any time in the past.
Due to the complete utilization of all funds, the company confirms that no information is being provided by way of Annexure-A as required under the regulation and circular.
The disclosure is signed by Aman Pravinkumar Patel, Wholetime Director of the company, and includes digital signature verification details.
Financial Impact
No financial impact disclosed as the company confirms complete utilization of all past issue proceeds with no unutilized funds remaining.